CAR-T cells, on the other hand already are armed with the antibodies and seek out tumor cells as a “ready-made killing machine.” Additionally, autologous CAR-T cells are activated ex vivo, typically by CD3, CD28, and/or cytokine treatment, providing a stimulant for killing tumor cells immediately upon dosing. This evidence concerns the gene CD28 and neoplasm.